Guidelines

I. Structuring of Centers for clinical application and multidisciplinary management of patients with CAR-T cells

II. CAR T-cell therapy for adult and pediatric patients with CD19+ acute lymphocytic leukemia

III. Anti-CD19 CAR-T cell therapy for patients with non-Hodgkin's lymphoma

IV. CAR T-cell therapy for patients with multiple myeloma

V. Quality control and manufacturing

VI. Accreditation Process

VII. Present and future of technologies for the production of CAR cell therapies

VIII. Preclinical models for the development of therapies with CAR T cells (in vitro and in vivo models)

Review Article: Compassionate Use and Clinical Trial of CAR-T Cells

Review Article: Cell Therapy in Solid Tumors

Special Article: Advanced therapy products in Brazil: regulatory landscape

Myeloproliferative neoplasms

Immune thrombocytopenia in adults

Myelodysplastic syndromes

Transfusion of Red Blood Cells

The treatment of acute myeloid leukemia

Neonatal screening and painful vaso-occlusive crisis in sickle cell disease

Beta-thalassemia major - regular blood transfusion therapy

The diagnosis and treatment for acute promyelocytic leukemia

The treatment of anemia of chronic renal failure using recombinant human erythropoietin

The Brazilian Society of Bone Marrow Transplantation on Hematopoietic Stem Cell

The diagnosis and management of multiple myeloma treatment

The diagnosis of primary immune thrombocytopenia in children and adolescents

The treatment of primary immune thrombocytopenia in children and adolescents

Use of convalescent plasma to treat patients with COVID-19

Guidelines on sickle cell disease: primary stroke prevention in children and adolescents

Guidelines on sickle cell disease: secondary stroke prevention in children and adolescents